Skip to main navigation Skip to search Skip to main content

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

  • Talitha I Verhoef
  • , William K Redekop
  • , Josep Darba
  • , Mary Geitona
  • , Dyfrig A Hughes
  • , Uwe Siebert
  • , Anthonius de Boer
  • , Anke-Hilse Maitland-van der Zee
  • , Rita Barallon
  • , Montserrat Briz
  • , Ann Daly
  • , Elisabeth Haschke-Becher (Co-author)
  • , Farhad Kamali
  • , Julia Kirchheiner
  • , Vangelis G Manolopoulos
  • , Munir Pirmohamed
  • , Frits R Rosendaal
  • , Rianne M F van Schie
  • , Mia Wadelius

    Research output: Contribution to journalReview articlepeer-review

    21 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)989-1002
    JournalPHARMACOGENOMICS
    Volume11
    Issue number7
    DOIs
    Publication statusPublished - 2010

    Keywords

    • ORAL ANTICOAGULANT-THERAPY
    • INTERNATIONAL NORMALIZED RATIO
    • WARFARIN THERAPY
    • BLEEDING COMPLICATIONS
    • ATRIAL-FIBRILLATION
    • CYTOCHROME P4502C9
    • ECONOMIC OUTCOMES
    • DOSE REQUIREMENT
    • CYP2C9
    • VKORC1

    Cite this